24 HOUR WU ALLOCATION
| Research | Percent |
|---|---|
|
ALZHEIMERS |
100% |
7 DAY WU ALLOCATION
| Research | Percent |
|---|---|
|
ALZHEIMERS |
93.51% |
|
PEPTIDOMIMETIC CD40L BINDING |
2.8% |
|
ENZYME DYNAMICS |
2.01% |
|
CANCER |
.95% |
|
ATWRI1 MUTANT SCREENING |
.73% |
12 WEEK WU ALLOCATION
| Research | Percent |
|---|---|
|
ALZHEIMERS |
62.17% |
|
ENZYME DYNAMICS |
8.89% |
|
ATGPA1 POST TRANSLATIONAL MODIFICATIONS |
8.26% |
|
ATSTP10 SUCROSE TRANSPORT |
5.67% |
|
ATGPA1 POST TRANSLATIONAL MODIFICATION DYNAMICS |
3.86% |
|
CANCER |
3.31% |
|
INFLUENZA |
2.95% |
|
MEMBRANE TRANSPORT |
1.17% |
|
ATSTP10 TRANSPORT SIMULATION |
1.14% |
|
RCA OLIGOMER STABILITY SIMULATIONS |
1.01% |
|
NIPAH VIRUS DECOY PROTEIN DYNAMICS |
.53% |
|
PEPTIDOMIMETIC CD40L BINDING |
.44% |
|
RCA OLIGOMERIC STABILITY TEMPERATURE SIMULATION |
.2% |
|
RCA STABILITY SIMULATIONS |
.2% |
|
ATWRI1 MUTANT SCREENING |
.11% |
|
SUCROSE TRANSPORTER ATSUC1 |
.07% |